The Ministry of Food and Drug Safety announced on the 23rd that it has approved a new treatment for lowering pulmonary artery pressure. It has approved Wonrebaerju (ingredient name Sotatercept) and Wonrebaerkitju (Sotatercept) 45 mg and 60 mg.
This is an imported rare drug that acts as an activin signaling inhibitor. When the activin-A levels of patients with pulmonary arterial hypertension rise, it lowers the levels, regulates blood vessels, and reduces blood pressure. Activin is a glycoprotein involved in cell proliferation, differentiation, and inflammatory responses.
This drug has been approved for use in improving exercise capacity in adults in conjunction with other treatments for pulmonary arterial hypertension. The ministry noted that it will ensure that safe and effective treatments are provided for diseases that threaten survival or are rare.